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ABSTRACT
Chemically modified antisense oligonucleotides
(ASOs) are widely used as a tool to functionalize
microRNAs (miRNAs). Reduction of miRNA level
after ASO inhibition is commonly reported to show
efficacy. Whether this is the most relevant endpoint
for measuring miRNA inhibition has not been
adequately addressed in the field although it has
important implications for evaluating miRNA target-
ing studies. Using a novel approach to quantitate
miRNA levels in the presence of excess ASO, we
have discovered that the outcome of miRNA inhibi-
tion can vary depending on the chemical modifica-
tion of the ASO. Although some miRNA inhibitors
cause a decrease in mature miRNA levels, we have
identified a novel 2’-fluoro/2’-methoxyethyl modified
ASO motif with dramatically improved in vivo
potency which does not. These studies show there
are multiple mechanisms of miRNA inhibition by
ASOs and that evaluation of secondary endpoints
is crucial for interpreting miRNA inhibition studies.
INTRODUCTION
MicroRNAs (miRNAs) are a class of noncoding RNAs
that regulate gene expression post-transcriptionally (1,2).
In mammals, regulatory roles have been identiﬁed for
miRNA in many areas of biology (3,4), highlighting
miRNA as an exciting new class of therapeutic targets
with broad applications. Antisense oligonucleotide (ASO)
inhibition of miRNA has been a useful tool for their func-
tionalization and shows promise as a therapeutic strategy.
Chemical modiﬁcation of ASOs to improve stability to
nucleasesandaﬃnity for targetRNA is generally necessary
for robust activity. Eﬀective targeting of miRNA by ASOs
with various backbone and 20 sugar modiﬁcations includ-
ing 20-O-methyl (20-OMe), 20-O-methoxyethyl (20-MOE),
20-ﬂuoro (20F) and locked nucleic acid (LNA) has been
reported by several groups in cell culture (5–9) and after
systemic delivery in vivo (10–13) and have been widely used
for miRNA functionalization.
In the course of our own screening eﬀorts to identify
more eﬀective anti-miRNA oligonucleotides, we recog-
nized the importance of a reliable endpoint to evaluate
miRNA inhibition. Measurement of miRNA levels by
northern blotting or RT–PCR is commonly reported to
assess miRNA inhibition. However, inhibition of miRNA
activity, measured by modulation of miRNA target genes,
without degradation of the miRNA has recently been
reported (10). In addition, hybridization-based measure-
ments of miRNA levels can be problematic, as they are
potentially subject to interference by the complementary
ASO present. If miRNA levels are not aﬀected by ASO
inhibition or cannot be measured reliably, a secondary
endpoint—modulation of a miRNA target gene—is
required to measure inhibition of miRNA activity.
We set out to develop a reliable method to measure
miRNA levels in the presence of ASO, to better under-
stand the outcome of miRNA inhibition and determine
how best to measure ASO eﬃcacy. We previously
showed that a uniformly modiﬁed 20-MOE phosphor-
othioate backbone ASO was an eﬀective inhibitor of the
abundant liver-expressed miR-122 in mice after systemic
delivery in saline (12), and reduced miR-122 levels. Using
our novel method to quantitate miRNA in the presence of
ASO, we have conﬁrmed this result. Our screening eﬀorts
have additionally identiﬁed a chimeric 20-F/MOE ASO
as a potent inhibitor of miRNA activity in vivo, when
measured by derepression of miRNA target genes.
Surprisingly, the mechanism of miRNA inhibition by
20-F modiﬁed ASOs does not involve degradation of the
miRNA. This suggests that there are multiple outcomes
of miRNA inhibition by ASOs and that evaluation of
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METHODS
Animal careand treatments
All animal experiments were conducted according to the
Institutional AAALAC Guidelines. Male C57BL/6 mice
were housed four to ﬁve animals per cage with a 12h light/
dark cycle. Oligonucleotides were dissolved in saline and
administered to mice based on body weight by intraperi-
toneal (i.p.) injection, twice weekly.
Northern blotting
Total RNA was puriﬁed using Trizol reagent (Invitrogen).
10mg total RNA in 1  TBE-Urea loading buﬀer
(Invitrogen) was separated on a 15% TBE-Urea polyacry-
lamide gel (Invitrogen) or a 14% TBE-Urea polyacryla-
mide gel with 20% formamide. Samples run on formamide
containing gels were also loaded in 20% formamide. RNA
was transferred to Hybond N+membranes (Amersham)
at 30V for 2hr and UV cross-linked. Blots were pre-
hybridized in Rapid-Hyb Buﬀer (GE Healthcare) for
1hr at 428C and then hybridized with a
32P end-labeled
DNA probe for 4hr at 428C. Blots were washed in
5  SSC buﬀer+0.1% SDS twice for 5min at room
temperature and exposed overnight. Quantitation was
done using a Storm 860 phosphoimager (Molecular
Dynamics) and ImageQuant software.
Oligonucleotide synthesis andpurification
20-MOE, 20-OMe, 20-MOE/LNA and 20-deoxy-20-Fluoro/
20-MOE-modiﬁed oligonucleotides were synthesized on
AKTA Oligopilot 10 (Amersham/GE Healthcare)
oligonucleotide synthesizer. The 20-MOE amidites were
prepared as reported (14–16). The LNA, 20-OMe and
20-deoxy-20-ﬂuoro modiﬁed pyrimidine nucleoside phos-
phoramidites were purchased from commercial sources.
The 20-deoxy-20-F purine nucleoside phosphoramidites
were synthesized as described in the literature (16,17).
Oligonucleotides were prepared as reported earlier (18)
with minor modiﬁcations described here. The 3min detri-
tylation step was performed with 6% DCA/toluene. A
0.1M solution of the phosphoramidites in anhydrous
acetonitrile was used for the synthesis. For sulfurization,
0.2M Phenylacetyl disulﬁde (PADS) in 1:1 3-picoline/
CH3CN was used with 6min contact time. After comple-
tion of the synthesis, solid support was treated with
triethyl amine:acetonitrile (1:1) for 30min. It was sus-
pended in a mixture of aqueous ammonium hydroxide
(30wt.%): ethanol (3:1) and heated at 558C for 9h to
complete the removal of all protecting groups.
The oligonucleotides were puriﬁed by ion exchange
chromatography on an AKTA Explorer (GE healthcare)
HPLC system on a strong anion exchange column (source
30 Q, GE Healthcare). Fractions containing full-length
oligonucleotides were pooled together (assessed by LC
MS analysis) and evaporated. The ASOs were desalted
by reverse phase HPLC to furnish modiﬁed
oligonucleotides in 30–40% yield based on the loading
of the solid support. All the modiﬁed oligonucleotides
were characterized by ion-pair-HPLC–MS analysis with
Agilent 1100 MSD system.
Competitor PNA assay
Competitor PNA was obtained from Panagene. PNA was
added to 10mg total RNA in 1  TBE-Urea loading buﬀer
(Invitrogen). Samples were mixed and heated at 958C for
3min prior to loading on 15% TBE-Urea polyacrylamide
gel (Invitrogen). Prior to electroblotting, the top portion
of the gel containing excess competitor PNA was cut and
separated from lower miRNA-containing portion. Use of
a 23-bp ﬂuoroscein-labeled oligonucleotide aided in gel
separation. After electroblotting, UV crosslinking, and
pre-hybridization as described, the pre-hybridization
buﬀer was exchanged for fresh buﬀer and blots were
then hybridized for 4h at 428C. Blots were washed in
5  SSC buﬀer+0.1% SDS (Invitrogen) twice for 5min
and exposed overnight.
RT–PCR analysis
qRT–PCR analysis was performed with a Prism 7700
Sequence Detector (Applied Biosystems). All RT-PCR
reagents were obtained from Invitrogen. ALDOA
primer/probe sequences: Forward primer, 50-AGGCTCT
TTCCCATCACTCTTG-30; Reverse primer, 50-GATGGC
AGATTTAGCATTCACAGA-30, Probe: 50-FAM-TGT
GCCCTCGTGTGCGGTG-30-TAMRA. Real-time
RT-PCR analysis of miR-122 levels performed with ABI
Taqman miRNA assay kit.
Tm measurements
Absorbance versus temperature curves were measured at
260nm using a Beckman DU 640 Spectrophotometer and
High Performance Temperature Controller. The buﬀer
contained 100mM Na
+, 10mM phosphate and 0.01mM
EDTA, pH 7.0 with suﬃcient Cl
  to achieve ionic neu-
trality. Oligonucleotide concentration was 4mM each
strand determined from the absorbance at 858C and
extinction coeﬃcients calculated according to Puglisi and
Tinoco (19). Tm’s of duplex formation were obtained from
ﬁts of data to a two-state model with linear sloping base-
lines (20).
Data analysis
ED50 calculations were performed using GraphPad Prism
software.
RESULTS
Novelchimeric 2’-F/MOE ASO potently inhibits
miR-122in vivo
We have evaluated a panel of over 60 chemically-modiﬁed
ASOs for their ability to inhibit the liver-expressed
miR-122 in mice after systemic delivery. Initially, a panel
of various 20sugar, heterocycle and backbone modiﬁca-
tions were evaluated (for an example, see Supplementary
Figure 1), and modiﬁcations that supported anti-miR
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ment in the anti-miR ASO. In the course of our screening
eﬀorts, we were faced with the question of how best to
evaluate miRNA inhibition. We and others had previously
demonstrated a derepression of ALDOA and other
miR-122 target genes at the mRNA level, reduced
plasma cholesterol, and an apparent reduction of miR-
122 levels measured by northern blotting after inhibition
of miR-122 in vivo (12,13). MiRNA level may be the most
direct measurement, but as outlined above, may not be
the expected outcome of ASO inhibition. As there are
well-validated target genes for miR-122, we compared
ASO activity by measuring their derepression by
RT-PCR. Several of the most active ASOs identiﬁed
from our screening eﬀorts were compared in a repeat
dosing study. Normal mice were treated intraperitoneally
(i.p.) with 25mg/kg ASO twice weekly for three weeks.
The 20-MOE ASO previously described (12) was com-
pared with 20-OMe, a chimeric 20-MOE/LNA and a 20F
modiﬁed ASO with two 20-MOE modiﬁcations on either
end (20-F/MOE) for added stability in vivo (Figure 1A).
All of the ASOs had fully modiﬁed phosphorothioate
backbones, which aids delivery to tissues without formu-
lation and provides stability to nuclease degradation (21).
The 20-F/MOE ASO was the most active as measured by a
7-fold increase in ALDOA mRNA in the liver compared
to saline-treated mice, and nearly 40% reduction in
plasma cholesterol (Figure 1C and D). The 20-MOE/
LNA compound was the next most active, resulting in a
5-fold increase in ALDOA mRNA and approximately
20% plasma cholesterol lowering. The activity of the
20-MOE ASO was similar to that previously reported,
with ALDOA mRNA levels increased 3.5-fold compared
to saline and a 20% reduction in plasma cholesterol.
However, treatment with the 20-OMe ASO, while causing
a3-foldincreaseinALDOA mRNA levels,didnot resultin
plasma cholesterol lowering. Measuring several other miR-
122 target genes gave similar results (data not shown).
There were only mild increases in plasma transaminase
levels in the mice treated with the 20-OMe, 20-MOE/LNA
and 20-F/MOE ASOs, and no signiﬁcant change in the
mice treated with the 20-MOE ASO (Figure 1B), indicating
that none of the ASOs caused liver toxicity.
The improved in vivo activity of the 20-F/MOE ASO over
the higher aﬃnity 20-MOE and 20-MOE/LNA ASOs was
surprising. We next compared its potency to the 20-MOE
ASO by performing a dose response. Normal mice were
treated i.p. with 6–50mg/kg 20-F/MOE or 20-MOE ASOs
twice weekly for 3 weeks. Treatment with the 20-MOE ASO
resulted in a dose-responsive increase in ALDOA mRNA
levels in the liver, reaching a maximum 3-fold increase
at the highest dose (Figure 2A). By contrast, all of the
20-F/MOE treatment groups showed a 4–5-fold increase
in ALDOA mRNA levels, suggesting that the maximal
eﬀect was achieved by the 12.5mg/kg dose level
(Figure 2A). The 20-F/MOE ASO was more eﬃcacious
and at least 8-fold more potent than the 20-MOE ASO,
since the lowest dose of 20-F/MOE was already more eﬀec-
tive than an 8-fold higher dose of 20-MOE ASO. A similar
result was observed for plasma cholesterol lowering
(Figure 2B). Evaluation of plasma transaminase levels
showed no signiﬁcant elevations in ALT from any of the
treated mice. However, a dose-dependent increase in spleen
weight at sacriﬁce was observed after treatment with the
20-F/MOE ASO which was not observed after 20-MOE
treatment (Figure 2C). This suggested that the 20-F/MOE
ASO may have a mild immunostimulatory eﬀect in the
mice. The introduction of three additional 20-MOE
modiﬁcations into the 20-F/MOE ASO was able to blunt
this immune stimulation without aﬀecting anti-miR-122
Figure 1. In vivo evaluation of miR-122 ASOs identiﬁes 20-F/MOE as potent miRNA inhibitor. Normal mice were treated i.p. with 25mg/kg dose of
miR-122 ASOs twice weekly for 3 weeks. Animals were sacriﬁced 48hr after the last dose. n=5. Error = SEM (A) Chemical modiﬁcation of anti-
miR ASOs evaluated for activity against miR-122 in mouse liver. All ASOs have completely modiﬁed phosphorothioate backbones. (B) Plasma
transaminase levels. (C) Real-time RT–PCR measuring levels of miR-122 target gene ALDOA in liver RNA. (D) Change in total plasma cholesterol
levels.
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previously been observed for phosphorothioate oligo-
deoxynucleotides (22). Interestingly, placement of
20-MOE modiﬁcations was only tolerated in the 50 half
of the ASO. Additional 20-MOE modiﬁcations in the 30
end of the ASO negatively aﬀected anti-miR activity.
We next compared the activity of the 20-F/MOE ASO
with a 15 mer LNA/DNA chimeric ASO (SPC3649),
which was reported to inhibit miR-122 activity in mice
(11). Additional studies had revealed that robust anti-
miR-122 activity could be measured after a single admin-
istration of the 20-F/MOE ASO, so the activity of the
ASOs was compared four days after a single treatment
of 1.2–100mg/kg. A six-base mismatch 20-F/MOE ASO
was also included. Levels of the miR-122 target gene
ALDOA were increased almost 4-fold after treatment
with the highest, 100mg/kg dose of the 20-F/MOE miR-
122 ASO, with near-maximal activity already observed at
the 11mg/kg dosing level (Figure 3A). The mismatched
20-F/MOE ASO had no eﬀect on ALDOA mRNA
levels. Treatment with the LNA/DNA ASO resulted in a
dose-dependent increase in ALDOA mRNA levels,
but was approximately 3.5-fold less potent than the
20-F/MOE ASO (calculated ED50 14mg/kg compared to
4mg/kg). Plasma cholesterol lowering followed a similar
trend for the three ASOs (Figure 3B). As measured by
miRNA target gene modulation, the 20-F/MOE ASO is
the most potent miRNA inhibitor reported to date.
Measuring miRNA levels inthe presenceof ASO
We next measured by northern blotting the miR-122 levels
in the livers of mice from the experiment described in
Figure 1. Krutzfeldt et al. (13) had reported that interfer-
ence of miRNA detection by ASO could be eliminated
by running the RNA samples in a denaturing gel contain-
ing 20% formamide, so northern blotting was performed
under these conditions (Figure 4A). Treatment with all
of the ASOs led to signiﬁcant reduction in the levels of
miR-122 detected, with no measurable signal from the
20-MOE/LNA or 20-F/MOE ASO-treated samples. How-
ever, the complete absence of miR-122 after treatment
with the high-aﬃnity 20-MOE/LNA led us to suspect
interference with miR-122 detection, in spite of the
presence of formamide, similar to what has been pre-
viously reported (23). Control experiments conﬁrmed
that in the case of the high-aﬃnity 20-MOE/LNA, as
well as the 20-F/MOE ASO, signiﬁcant interference with
miR-122 detection was observed when the ASO was added
to liver tissue lysates from untreated mice (Figure 4B).
Although phosphorothioate backbone-modiﬁed 20-OMe
and 20-MOE ASOs only minimally interfered with miR-
122 detection, the higher aﬃnity phosphodiester back-
bone 20-OMe and 20-MOE ASO interfered substantially.
A similar pattern of interference by the ASOs with
Taqman RT-PCR detection of miR-122 was also seen
(Figure 4C).
Figure 2. Improved potency and eﬃcacy of 20-F/MOE compared to 20-MOE ASO. Normal mice were treated i.p. with indicated doses of miR-122
ASOs twice weekly for 3 weeks, and animals were sacriﬁced 48hr after the last dose. n=5 Error = SEM (A) Real-time RT–PCR measuring levels of
miR-122 target gene ALDOA in liver RNA. (B) Change in total plasma cholesterol levels. (C) Spleen weight.
Figure 3. Improved potency of 20-F/MOE compared to 15 mer LNA/
DNA ASO (SPC3649) after single administration. Normal mice were
treated i.p. with a single administration of the indicated dose of miR-
122 ASO, and anti-miR-122 activity was measured four days later.
n=2–4 Error=SEM. (A) Real-time RT–PCR measuring miR-122
target gene mRNA ALDOA in liver RNA. (B) Change in total
plasma cholesterol levels from baseline.
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the northern blot corresponded to the aﬃnity of the ASO
for the miRNA, although the data were not entirely con-
sistent with this (e.g. 20-F/MOE ASO). One possible expla-
nation is that recovery of the 20-F/MOE ASO is greater
than the 20-MOE ASO during the RNA puriﬁcation pro-
cess, leading to greater interference with miR-122 detec-
tion during northern blotting. To investigate this, we
measured the recovery of radiolabeled ASOs spiked into
Trizol lysates of mouse liver tissue (Supplementary
Figure 3A). Recovery of all the modiﬁed ASOs was simi-
lar, however, making it unlikely that diﬀerential ASO
recovery accounted for the diﬀerent degrees of interfer-
ence by the ASOs.
We observed in these experiments that while a large
portion of the ASOs persist through the RNA preparation
process, the majority of ASO remains in the organic phase
during the ﬁrst step of the Trizol isolation protocol. Some
ASOs may remain bound to the miRNA during the Trizol
puriﬁcation, partitioning the miRNA into the organic
phase during the phase separation step of the RNA isola-
tion. To evaluate this, we measured recovery of a radiola-
beled miR-122 RNA through the Trizol puriﬁcation
process in the presence of the ASOs (Supplementary
Figure 3B). Overall recovery of the miRNA in the pre-
sence of the high aﬃnity 20-MOE/LNA ASO was 4-fold
reduced compared to the other ASOs, none of which
had any signiﬁcant eﬀect on miR-122 recovery. The
recovery of miR-122 during the precipitation step was
similar for all the ASOs, indicating that the miRNA is
primarily lost during the initial phase separation. We
also observed other high aﬃnity ASOs, including the
antagomir described by Krutzfeldt et al. (13), similarly
retaining the miRNA in the organic phase (data not
shown).
To more accurately quantitate miRNA levels in the pre-
sence of ASO, we devised a strategy to free the miRNA
from the ASO after RNA puriﬁcation by adding an excess
of high aﬃnity peptide nucleic acid (PNA) complementary
to the ASO to compete for its binding, thereby making it
available for northern hybridization (Figure 5A). When
the RNA sample is separated on a polyacrylamide gel
by electrophoresis, the PNA-bound ASO is shifted on
the gel and migration of free PNA will also be retarded
compared to the miRNA due to its neutral charge. This is
important, as the PNA is the same sequence as the
miRNA and will be detected by the northern probe.
The feasibility of this approach was shown by its ability
to free radiolabeled miR-122 from a miRNA-ASO duplex
(Supplementary Figure 4). We next evaluated the compet-
itor PNA’s ability to restore northern detection of miR-
122 in total liver RNA in the presence of ASO (Figure 5B).
Increasing amounts of ASO were added to Trizol liver
lysate, and RNA was isolated. Competitor PNA was
added to the puriﬁed RNA samples, which were separated
on a denaturing gel and northern blotting for miR-122
was performed. Under conditions in which the 20-MOE
and 20-OMe ASOs interfered with miRNA detection, the
competitor PNA restored miR-122 detection, although in
the case of the 20-MOE ASO the recovery was not com-
plete. The competitor PNA also restored the miR-122
signal in the presence of 1 and 10mg of the 20-F/MOE
ASO, but only partially in the samples containing
100mg of the ASO. The inability of the PNA competitor
to restore the miR-122 signal in the presence of the
20-MOE/LNA ASO was not surprising, since miR-122 is
retained by this ASO in the organic phase during RNA
puriﬁcation and is therefore not present to be recovered.
miR-122 levels afterin vivoASO inhibition
We next used this assay to evaluate the eﬀect of in vivo
ASO inhibition on miR-122 levels. Competitor PNA was
added to mouse liver RNA from the study described in
Figure 1, and northern blotting for miR-122 was per-
formed (Figure 6). The tissue level of the 20-MOE ASO
after this 3 weeks dosing regimen is not expected to be in a
range, where interference with miRNA detection is likely.
Without any competitor PNA, a 5-fold reduction in
miRNA levels was measured and addition of competitor
PNA did not recover any further signal. While miR-122
detection in the RNA from 20-F/MOE ASO-treated mice
was completely inhibited, 80% of the miRNA signal could
be restored by addition of the competitor PNA.
Surprisingly, the most potent compound caused only a
modest change in miRNA levels.
Figure 4. Some anti-miRNA ASOs interfere with miRNA detection.
(A) Northern blotting for miR-122 in liver RNA from mice treated
as described in Figure 1. (B) Inhibition of miR-122 detection by north-
ern blotting after spiking the indicated amount of ASO (mg) into Trizol
lysates containing 50mg liver tissue before RNA puriﬁcation. PS, phos-
phorothioate backbone; PO, unmodiﬁed phosphodiester backbone.
RNA is separated on polyacrylamide gel containing 8M urea and
20% formamide. (C) Real-time RT–PCR detection of miR-122 with
TaqMan miRNA Assay in same samples shown in (B).
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Our data suggest that the 20-MOE and 20-F/MOE ASOs
inhibit miRNA activity by diﬀerent mechanisms. While
the 20-F/MOE apparently acts by sequestering the
miRNA, the mechanism of miRNA reduction by the
20-MOE or 20-OMe ASOs is currently unknown.
The ASOs may be accelerating turnover of the mature
miRNA or acting on the precursor to prevent miRNA
processing. Any of these mechanisms may have conse-
quences for the miRNA pathway, if it results in
sequestration, accelerated turnover or increased availabil-
ity of RISC. We therefore evaluated the levels of other
miRNAs in the liver after inhibition of miR-122 with
the 20-MOE and the 20-F/MOE ASOs. Proﬁling of
miRNA expression after 4 weeks of miR-122 inhibition
with the 20-MOE ASO or 6 weeks of inhibition with the
20-F/MOE ASO, revealed that few miRNAs were modu-
lated as a result of ASO treatment (Supplementary
Table 1). The changes in miRNA levels were small
(<2-fold) and not consistently up or downregulated,
showing that in vivo inhibition of miR-122 by either
Figure 5. Competitor PNA strategy recovers detection of miRNAs in the presence of anti-miRNA ASOs. (A) Competitor PNA strategy to recover
detection of miRNAs in the presence of anti-miR ASOs. (B) Recovery of miR-122 detection in total liver RNA in presence of ASO by addition of
competitor PNA.
Figure 6. Most potent 20-F/MOE ASO does not cause substantial miRNA reduction. Northern blotting for miR-122 after separation of RNA by
denaturing PAGE in presence of competitor PNA. Normal mice were treated i.p. with 25mg/kg dose of miR-122 ASOs twice weekly for 3 weeks.
Nucleic Acids Research, 2009, Vol. 37, No. 1 75ASO did not result in substantial dysregulation of miRNA
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DISCUSSION
The technical diﬃculty of measuring miRNA levels in the
presence of abundant ASO has made the interpretation of
many published miRNA inhibition studies challenging.
The level of anti-miR-122 ASO accumulated in the liver
after in vivo dosing may be as much as hundreds of micro-
grams per gram of liver tissue, with the majority of the
ASO not bound to miRNA. The ratio of transfected ASO
to miRNA in cell culture studies will also be high, leading
to detection artifacts. While interference with miRNA
detection or detection of a miRNA–ASO duplex is an
indication that ASO is associated with the cell or tissue,
it is not a measure of inhibition of miRNA activity.
Furthermore, if miRNA degradation is not the primary
outcome of ASO inhibition, measuring miRNA levels,
even if done reliably, will not correlate with miRNA activ-
ity. Here we have described a novel strategy to measure
miRNA levels in the presence of ASO, involving the addi-
tion of a PNA complementary to the ASO to compete it
away from the miRNA, freeing it for northern blot
detection. The results show that although treatment with
the 20-MOE ASO does result in reduced miRNA levels,
the 20-F/MOE ASO potently inhibits miRNA activity
in vivo without substantial reduction in miR-122 levels.
This suggests that for the most eﬀective anti-miRNA
ASO, measuring miRNA levels on a northern blot or by
RT–PCR is not informative, making the identiﬁcation of a
secondary endpoint, a miRNA target gene, absolutely
critical for interpretation of miRNA inhibition studies.
The availability of well-validated miR-122 target genes
that are robustly and dose-dependently modulated after
miRNA inhibition has allowed us to usefully compare
the potency of chemically modiﬁed miRNA inhibitors
in vivo. However, in most miRNA inhibition studies,
target genes are not known or only modestly modulated,
making it diﬃcult to assess miRNA inhibition.
Consequently, many phenotypic outcomes of miRNA
inhibition studies are diﬃcult to interpret.
Several studies have evaluated the eﬀects of sugar and
backbone oligonucleotide modiﬁcations on anti-miRNA
activity in cell culture, but this is the ﬁrst study directly
comparing the eﬀectiveness of a panel of modiﬁcations
in vivo. Our own in vitro studies evaluating anti-miRNA
ASOs in Hela cells had highlighted the 20-F modiﬁcation
as a surprisingly potent modiﬁcation, and those ﬁndings
have translated well to the in vivo setting. The reasons for
the dramatic improvement in potency by the 20-F/MOE
ASO are not clear. It is at least partly independent of its
aﬃnity to the target miRNA, as it was more potent
than the full-length 20-MOE/LNA ASO with higher mea-
sured Tm. Accumulation of the 20-F/MOE and 20-MOE
ASOs in the mouse liver are similar, suggesting that
improved tissue delivery is not responsible for the
improved potency. The 20-F modiﬁcation may allow
more favorable interactions with the miRNA in RISC.
The eﬀect of the 20-F/MOE ASO was sequence-speciﬁc,
as a six-base pair mismatch of the same chemistry and
20-F/MOE ASOs targeting several other miRNAs (data
not shown), did not aﬀect miR-122 target genes or
plasma cholesterol. This argues against the possibility
that the anti-miR-122 activity is an indirect result of
the mild pro-inﬂammatory eﬀects we observed with the
parent 20-F/MOE ASO. Further dissection of the con-
tributions of length, aﬃnity and pharmacokinetic prop-
erties to the anti-miR activity of the 20F/MOE and
LNA/DNA compounds should improve our understand-
ing of the structure-activity relationship. Clariﬁcation of
how inhibition with the 20-MOE ASO leads to miRNA
degradation, while the more potent 20-F/MOE ASO does
not, may give additional insight into the mechanisms of
anti-miR inhibition and suggest new strategies for miRNA
targeting.
The growing body of miRNA research is conﬁrming
that miRNA are an important class of regulators in
many areas of biology. The application of antisense tech-
nology for functionalization and therapeutic targeting of
miRNAs shows great promise. Twenty years of invest-
ment in the technology have advanced understanding of
how oligonucleotide chemical modiﬁcations aﬀect stabil-
ity, aﬃnity to RNA and uptake into tissues. This experi-
ence should accelerate the development of ASOs targeting
miRNAs. However, our understanding of the optimal che-
mical modiﬁcations for anti-miRNA ASOs is only at the
beginning, and targeting of miRNAs with ASOs presents
challenges for evaluating target engagement which must
be addressed in order to interpret ASO inhibition studies.
Identiﬁcation of the 20-F/MOE ASO as a particularly
eﬀective in vivo inhibitor of miR-122, and clariﬁcation of
the outcome of miRNA inhibition with ASO represents
signiﬁcant progress in both of these areas.
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